Last reviewed · How we verify

NCT03440099

Sex-specific Adaptation to Resistance Training in Older Adults

Status unknown NA Last updated 28 June 2022
What this trial tests

NA trial testing Resistance exercise training in Biological Aging in 50 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
31 March 2024
31 March 2024

Quick facts

Lead sponsorUniversity of Massachusetts, Amherst
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment50
Start date1 January 2018
Primary completion31 March 2024
Estimated completion31 March 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Massachusetts, Amherst

Who can join

Adults 65 to 75, any sex, with Biological Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In general, men and women experience differing degrees of age-related decreases in physical function, with women having a greater prevalence of functional limitations and disability. A key predictor of this decrease in functional capacity is the reduction in leg muscle maximal power (product of force and velocity), which can be improved with exercise training. However, the development of exercise interventions to optimally improve skeletal muscle function in older adults has been difficult, in part because we now know that men and women respond differently to the same exercise training stimulus. In fact, the fundamental mechanisms by which habitual exercise improves physical function in older adults are still not well understood. The proposed studies are designed to address these knowledge gaps by examining the molecular and cellular mechanisms underlying the response to two distinct exercise training paradigms, and determining how these responses differ between older men and women. The investigators hypothesize that molecular, cellular and whole muscle contractile performance will be most improved in men by traditional low-velocity, high-load resistance training, and in women by high-velocity, low-load power training. Moreover, sex-specific structural responses in myofilament remodeling, protein expression and post-translational modifications will explain these sex-specific performance adaptations to each modality. To test these hypotheses, data will be gathered from 50 healthy, sedentary older men and women (65-75 years) prior to and following a 16-week unilateral exercise training program in which one leg undergoes resistance training and the other power training. The Specific Aims of this project are to identify the sex-specific effects of low-velocity resistance training versus high-velocity power training on: Aim 1) skeletal muscle function at the molecular, cellular and whole muscle levels, and Aim 2) protein expression and modification as well as size at the molecular and cellular levels. The within subject, unilateral intervention design provides a powerful model to minimize the effects of between-subject variability, and the translational approach will take advantage of our unique expertise with state-of-the-art measures from the molecular to whole body levels.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Epigenetic regulation of aging: implications for interventions of aging and diseases.
    Wang K, Liu H, Hu Q, Wang L, et al · · 2022 · cited 406× · PMID 36336680 · DOI 10.1038/s41392-022-01211-8

Verify or expand the search:

Other trials of Resistance exercise training

Trials testing the same drug.

Other recruiting trials for Biological Aging

Currently open trials in the same condition.

Other University of Massachusetts, Amherst trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03440099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing